全文获取类型
收费全文 | 1067篇 |
免费 | 96篇 |
国内免费 | 19篇 |
专业分类
儿科学 | 77篇 |
妇产科学 | 5篇 |
基础医学 | 135篇 |
口腔科学 | 63篇 |
临床医学 | 122篇 |
内科学 | 196篇 |
皮肤病学 | 46篇 |
神经病学 | 28篇 |
特种医学 | 241篇 |
外科学 | 82篇 |
综合类 | 32篇 |
预防医学 | 48篇 |
眼科学 | 13篇 |
药学 | 31篇 |
1篇 | |
肿瘤学 | 62篇 |
出版年
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 10篇 |
2019年 | 9篇 |
2018年 | 16篇 |
2017年 | 7篇 |
2016年 | 12篇 |
2015年 | 30篇 |
2014年 | 26篇 |
2013年 | 42篇 |
2012年 | 25篇 |
2011年 | 24篇 |
2010年 | 54篇 |
2009年 | 52篇 |
2008年 | 22篇 |
2007年 | 34篇 |
2006年 | 25篇 |
2005年 | 26篇 |
2004年 | 16篇 |
2003年 | 27篇 |
2002年 | 20篇 |
2001年 | 15篇 |
2000年 | 5篇 |
1999年 | 22篇 |
1998年 | 81篇 |
1997年 | 76篇 |
1996年 | 59篇 |
1995年 | 53篇 |
1994年 | 38篇 |
1993年 | 46篇 |
1992年 | 8篇 |
1991年 | 24篇 |
1990年 | 15篇 |
1989年 | 43篇 |
1988年 | 35篇 |
1987年 | 25篇 |
1986年 | 18篇 |
1985年 | 18篇 |
1984年 | 9篇 |
1983年 | 13篇 |
1982年 | 14篇 |
1981年 | 14篇 |
1980年 | 15篇 |
1979年 | 3篇 |
1978年 | 13篇 |
1977年 | 11篇 |
1976年 | 10篇 |
1975年 | 8篇 |
1954年 | 1篇 |
排序方式: 共有1182条查询结果,搜索用时 46 毫秒
991.
Mutations in N-ras predominate in acute myeloid leukemia 总被引:15,自引:5,他引:15
Bos JL; Verlaan-de Vries M; van der Eb AJ; Janssen JW; Delwel R; Lowenberg B; Colly LP 《Blood》1987,69(4):1237-1241
Using synthetic oligomers we investigated fresh samples of acute myeloid leukemia (AML) for the presence of mutated ras oncogenes. Our original results showed that five of eight samples contained a mutation in codon 13 of the N-ras gene. In a subsequent study involving 37 samples, we found only one N-ras-13 mutation, and, in addition, mutations in codon 61 of the N-ras gene in four cases and a mutation in codon 12 of the Ki-ras gene in two cases. Amplification of ras genes was not observed. We conclude that in approximately 20% to 25% of AML cases, a mutated ras oncogene is present, predominantly the N-ras gene. The occurrence of mutations does not correlate with the cytological features of the leukemia. 相似文献
992.
Blast cells from 100 cases of acute leukemia were evaluated for the presence of methylthioadenosine phosphorylase (MTAase), an enzyme important in polyamine metabolism. Ten cases (10%) had undetectable levels of MTAase activity. Of the 10, 5 had acute lymphoblastic leukemia (ALL), 3 had acute myeloblastic leukemia (AML) and 2 expressed mixed lineage markers as determined by immunophenotyping. A relatively high frequency (38%) of MTAase deficiency was seen in ALL of T-cell origin. Nonmalignant hematopoietic cells from three patients with MTAase-deficient leukemias had readily detectable enzyme activity. Chromosomal abnormalities were detected in four of the seven MTAase- deficient cases in which karyotypic analysis was performed. No consistent karyotypic defect was apparent, and only one case displayed changes in chromosome 9, the putative location of the MTAase structural gene. The clinical findings among the enzyme-deficient cases were unremarkable except that all patients were male (P less than .01). Only one patient had "lymphomatous" features. We conclude that MTAase deficiency occurs in a wide variety of acute leukemias, that the lack of enzyme activity is specific to the malignant cells, and that an increased incidence occurs in ALL of T-cell origin. Furthermore, no specific gross chromosomal abnormality is associated with the enzyme deficiency. The marked male predominance in patients with MTAase- deficient acute leukemias suggests involvement of the X chromosome in the loss of enzyme activity. The absence of MTAase in some leukemias may be therapeutically exploitable. 相似文献
993.
994.
Watson MS; Carroll AJ; Shuster JJ; Steuber CP; Borowitz MJ; Behm FG; Pullen DJ; Land VJ 《Blood》1993,82(10):3098-3102
Of 1,036 children with newly diagnosed non-T, non-B acute lymphoblastic leukemia (ALL) and a demonstrated cytogenetic abnormality treated on the frontline Pediatric Oncology Group (POG) therapeutic trial 8602, there were 33 patients with trisomy 21 as the sole abnormality. Of these 33, 14 had Down syndrome (DS). Although the non-DS (NDS) trisomy 21 cases tended to be older than the DS cases, there were no other significant differences in clinicobiologic features nor in treatment outcomes between the DS and NDS groups, nor between the entire trisomy 21 group and the other chromosome abnormality group. Among NDS patients with +21 and one additional abnormality, +X, +16, -20, and structural abnormalities involving 6q or 12p were common findings. Kaplan-Meier event-free survival (EFS) curves showed a 4-year EFS of 80% (SE, 12%) in NDS trisomy 21 cases, 71% (SE, 22%) in DS cases with trisomy 21 as the sole abnormality, and 69% (SE, 2%) in cases with other chromosome abnormalities. Trisomy 21 as a sole acquired abnormality in NDS patients suggests a good prognosis. 相似文献
995.
996.
An Wouters Bea Pauwels Filip Lardon Greet GO Pattyn Hilde AJ Lambrechts Marc Baay Paul Meijnders Jan B Vermorken 《BMC cancer》2010,10(1):441
Background
Based on their different mechanisms of action, non-overlapping side effects and radiosensitising potential, combining the antimetabolites pemetrexed (multitargeted antifolate, MTA) and gemcitabine (2',2'-difluorodeoxycytidine, dFdC) with irradiation (RT) seems promising. This in vitro study, for the first time, presents the triple combination of MTA, dFdC and irradiation using various treatment schedules. 相似文献997.
998.
999.
1000.